Skip to main content
Have a personal or library account? Click to login
Association of galectin-3 with echocardiographic parameters in acute COVID-19 heart failure phenotypes and a post-acute comparator cohort Cover

Association of galectin-3 with echocardiographic parameters in acute COVID-19 heart failure phenotypes and a post-acute comparator cohort

Open Access
|Jul 2026

References

  1. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and cardiovascular disease. Circulation. 2020;141(20):1648-55. DOI:10.1161/CIRCULATIONAHA.120.046941
  2. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259-60. DOI:10.1038/s41569-020-0360-5
  3. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system. JAMA Cardiol. 2020;5(7):831-40. DOI:10.1001/jamacardio.2020.1286
  4. Lala A, Johnson KW, Januzzi JL, Russak AJ, Paranjpe I, Richter F, et al. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J Am Coll Cardiol. 2020;76(5):533-46. DOI:10.1016/j.jacc.2020.06.007
  5. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052-9. DOI:10.1001/jama.2020.6775
  6. Rey JR, Caro-Codón J, Rosillo SO, Iniesta ÁM, Castrejón-Castrejón S, Marco-Clement I, et al. Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. Eur J Heart Fail. 2020;22(12):2205-15. DOI:10.1002/ejhf.1990
  7. Goyal P, Reshetnyak E, Khan S, Murphy CA, Corona AG, Voto T, et al. Clinical characteristics and outcomes of adults with a history of heart failure hospitalized for COVID-19. Circ Heart Fail. 2021;14(9):e008354. DOI:10.1161/CIRCHEARTFAILURE.121.008354
  8. Singh J, Bhagaloo L, Sy E, Lavoie AJ, Dehghani P, Bardutz HA, et al. Cardiac impairments in postacute COVID-19 with sustained symptoms: a review of the literature and proof of concept. Physiol Rep. 2022;10(16):e15430. DOI:10.14814/phy2.15430
  9. Venkatesan P. NICE guideline on long COVID. Lancet Respir Med. 2021;9:129. DOI:10.1016/S2213-2600(21)00031-X
  10. Huang L, Li H, He B, et al. Prevalence of cardiovascular symptoms in post-acute COVID-19 syndrome: a meta-analysis. BMC Med. 2025;23:70. DOI:10.1186/s12916-025-03908-3
  11. Sliwa K, et al. Long COVID syndrome, mortality and morbidity in patients hospitalized with COVID-19 from 16 countries: the World Heart Federation Global COVID-19 Study. Glob Heart. 2025;20(1):66. DOI:10.5334/gh.1452
  12. Garcia-Revilla J, Deierborg T, Venero JL, Boza-Serrano A. Hyperinflammation and fibrosis in severe COVID-19 patients: Gal-3, a target molecule to consider. Front Immunol. 2020;11:2069. DOI:10.3389/fimmu.2020.02069
  13. Havaldar AA, Kumar MV, Kumar R, Yarramalle SP, Khan MS, Misra KC, et al. Echocardiographic parameters in COVID-19 patients and their association with ICU mortality: a prospective multicenter observational study. Ultrasound J. 2023;15(1):38. DOI:10.1186/s13089-023-00336-3
  14. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. DOI:10.1161/CIR.0000000000001073
  15. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39. e14. DOI:10.1016/j.echo.2014.10.003
  16. Lassen MCH, Skaarup KG, Sengeløv M, et al. Recovery of cardiac function following COVID-19. Eur J Heart Fail. 2021;23(11):1909-18. DOI:10.1002/ejhf.2347
  17. de Boer RA, van der Velde AR, Mueller C, van Veldhuisen DJ, Anker SD, Peacock WF, et al. Gal-3: a modifiable risk factor in heart failure. Cardiovasc Drugs Ther. 2014;28(3):237-46. DOI:10.1007/s10557-014-6520-2
DOI: https://doi.org/10.2478/rrlm-2026-0022 | Journal eISSN: 2284-5623 | Journal ISSN: 1841-6624
Language: English
Page range: 213 - 220
Submitted on: Apr 19, 2026
Accepted on: Jun 17, 2026
Published on: Jul 11, 2026
In partnership with: Paradigm Publishing Services

© 2026 Nana Egiashvili, Nona Kakauridze, Ketevan Kartvelishvili, Nino Gvajaia, Davit Kartvelishvili, Levan Ratiani, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution 4.0 License.